Globus Medical, Inc. $GMED Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC increased its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 241.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 340,452 shares of the medical device company’s stock after purchasing an additional 240,642 shares during the quarter. SG Americas Securities LLC’s holdings in Globus Medical were worth $29,333,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. SBI Securities Co. Ltd. lifted its position in Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after buying an additional 167 shares during the last quarter. Advisory Services Network LLC acquired a new stake in shares of Globus Medical during the third quarter valued at about $26,000. EverSource Wealth Advisors LLC increased its position in shares of Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 197 shares during the last quarter. Larson Financial Group LLC raised its stake in shares of Globus Medical by 83.4% in the 4th quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock valued at $46,000 after acquiring an additional 242 shares during the period. Finally, Parallel Advisors LLC raised its stake in shares of Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after acquiring an additional 173 shares during the period. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Barclays upped their price objective on shares of Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Wall Street Zen lowered Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Piper Sandler decreased their price target on Globus Medical from $115.00 to $100.00 and set an “overweight” rating on the stock in a research note on Monday, June 15th. Wells Fargo & Company lowered their price target on Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Finally, Truist Financial set a $115.00 price objective on Globus Medical in a research note on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $105.00.

Globus Medical News Summary

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research raised its EPS forecasts for Globus Medical across several periods, including Q3 2026, Q1 2027, Q2 2027, FY2027, and FY2028, signaling improving earnings expectations.
• Positive Sentiment: The analyst firm maintained a Strong-Buy rating, which can support investor confidence in Globus Medical’s growth outlook.
• Neutral Sentiment: Several recent Zacks articles also discussed GMED’s valuation and macro/currency headwinds, suggesting the company still faces some growth and margin pressures despite the favorable estimate revisions. Article Title
• Neutral Sentiment: An earlier article noted GMED’s Q1 beat and the potential impact of foreign exchange pressures, which may keep investors focused on margin trends as well as revenue growth. Article Title
• Negative Sentiment: One Zacks update slightly lowered Q4 2027 EPS estimates, a small cautionary note, though it was offset by upgrades elsewhere.

Insider Buying and Selling

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the transaction, the director owned 510,175 shares in the company, valued at $41,201,733. The trade was a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 18.38% of the stock is owned by corporate insiders.

Globus Medical Stock Performance

Shares of GMED opened at $80.07 on Wednesday. The company’s 50-day simple moving average is $84.16 and its 200-day simple moving average is $87.51. Globus Medical, Inc. has a 1 year low of $51.79 and a 1 year high of $101.40. The stock has a market capitalization of $10.87 billion, a PE ratio of 18.62, a P/E/G ratio of 1.63 and a beta of 0.95.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. During the same quarter in the previous year, the business posted $0.68 earnings per share. The business’s quarterly revenue was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, sell-side analysts predict that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.